The area under the curve (AUC) values did not change significantly (Table 6)
Elite : A concentrated dose for addressing visible texture and fine lines
2013 May;1830(5):3143-53
Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF
In this trial, a subgroup of patients was assessed for organ-specific insulin sensitivity, hepatic lipid handling, and adipose dysfunction: the results showed that liraglutide improved hepatic and adipose insulin sensitivity and reduced the hepatic de novo lipogenesis [77], a key component of the hepatic fat accumulation in NASH
In Cleveland Clinic's 2025 analysis of real-world use, semaglutide 2.4 mg produced mean weight loss of approximately 14.1% at one year versus the ~15% trial number, and tirzepatide produced approximately 16.5% versus the 22% trial number
